NY-COTY
1.3.2024 14:31:34 CET | Business Wire | Press release
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE: PVH), and Calvin Klein Fragrances, a division of Coty Inc. (NYSE: COTY), today unveil actor and musician Idris Elba and his wife, model and human rights activist Sabrina Elba as the faces of Calvin Klein ETERNITY AROMATIC ESSENCE, the newest addition to the ETERNITY fragrance portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301420936/en/
Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign (Photo: Business Wire)
Shot by Mert Alas, the campaign offers a fresh and impactful take on ETERNITY’s timeless dream of eternal love, capturing Idris and Sabrina in moments of intimacy set to a bespoke cover of “Fever” by FKA twigs. The striking campaign imagery is inspired by profound connection and the essence of desire, paying tribute to ETERNITY’s legacy of sensuality by partnering with an authentic couple with a deep connection to the brand. The advertising campaign will be featured globally and supported by digital, social, print, and TV.
“Calvin Klein’s ETERNITY campaigns have always shown love that was intimate and real. It’s an honor to have our romance recognized for its authenticity, and have our commitment captured in this campaign. We are excited to be a part of ETERNITY’s iconic, timeless love story,” said Idris and Sabrina jointly.
CALVIN KLEIN ETERNITY AROMATIC ESSENCE FOR MEN and FOR WOMEN are elevated and bold aromatic fragrances, connected by a unique coconut note.
ETERNITY AROMATIC ESSENCE FOR MEN is a highly contrasted aromatic gourmand, crafted by principal perfumers Daphné Bugey and Frank Voelkl of Firmenich. The fragrance opens with fresh juniper berry essence with woody and gin-like facets. At the heart, the radiance of cardamom adds a spicy quality balanced by a sweet and floral lavender note. The seductive warmth of comforting coconut adds a sexy gourmand twist.
ETERNITY AROMATIC ESSENCE FOR WOMEN is a fresh, floral gourmand, created by perfumers Véronique Nyberg and Julie Massé of Mane. The captivating composition’s powerful freshness puts a modern twist on a floral fragrance. It opens with aromatic floral hints of lavender. At the heart, a sparkling coconut water accord unveils a vibrant gourmand, contrasted by an alluring dry down of sensual woods at the base.
The fragrances’ signature bottles and outer cartons have been reimagined with elevated codes and luxurious finishes. Inspired by the vibrancy of gemstones, the scents are housed in lacquered teal green glass bottles. Maintaining the shape and silver cap of the iconic original ETERNITY fragrances, the updated packaging exudes sensuality.
About Idris and Sabrina Elba
Idris Elba is an award-winning actor, producer, director, and musician continually securing his place as one of the most versatile performers in Hollywood. In 2016, he became the first male actor to receive dual SAG awards in one evening - Outstanding Performance by a Male Actor in a Supporting Role and Outstanding Performance in a TV Movie or Miniseries.
A multi-hyphenate in every sense of the word Sabrina Elba is not only a model, entrepreneur, and UN Goodwill Ambassador for the International Fund for Agricultural Development (IFAD) but also works with various civil society orgs like Farm Africa, Conservation International, and the European board for Global Citizen, receiving accolades like the TIME100 Impact award and the Crystal Award from the World Economic Forum.
About Calvin Klein
Calvin Klein is one of the world’s leading global fashion lifestyle brands with a history of bold, non-conformist ideals that inform everything we do. Founded in New York in 1968, the brand’s minimalist and sensual aesthetic drives our approach to product design and communication, creating a canvas that offers the possibility of limitless self-expression. The Calvin Klein brands – CK Calvin Klein, Calvin Klein, Calvin Klein Jeans, Calvin Klein Underwear, and Calvin Klein Performance – are connected by the intention and purpose of elevating everyday essentials to globally iconic status. Each of the brands has a distinct identity and position in the retail landscape, providing us the opportunity to market a range of universally appealing products to domestic and international consumers with a variety of needs. Our products are underpinned by responsible design, high-quality construction, and the elimination of all unnecessary details. We strive for unique and dimensional pieces that continuously wear well and remain relevant season after season. Global retail sales of Calvin Klein products were approximately $9.3 billion in 2022.
Calvin Klein continues to solidify its position as an innovator of emerging digital platforms and modern marketing campaigns. PVH acquired Calvin Klein in 2003 and continues to oversee a focused approach to growing the brand’s worldwide relevance, presence, and long term growth.
About Coty Inc.
Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. We serve consumers around the world, selling prestige and mass market products in more than 125 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at coty.com or on LinkedIn and Instagram.
ADVERTISING CREDITS:
Creative Direction: Calvin Klein
Campaign Videos: Mert Alas
Advertising Campaign Images: Mert Alas
EDITORIAL CREDIT:
TERNITY AROMATIC ESSENCE FOR WOMEN CALVIN KLEIN
ETERNITY AROMATIC ESSENCE FOR MEN KLEIN
SOCIAL MEDIA: #CKEternity
BRAND HANDLE: @calvinklein
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301420936/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom